Has Marshall Mazepa, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,189 in general payments to Marshall Mazepa, MD across 3 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marshall Mazepa, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marshall Mazepa, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marshall Mazepa, MD

Hematology & Oncology · Minneapolis, MNNPI 1174569354

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,008 of the $10,189 with a category attached, or 98.2%. Novartis accounts for 67.7% of it on its own, with 1 other manufacturer making up the rest.

$10,189in general payments, 2019–2025

Across 3 payments — averaging $3396.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$7K
Sanofi$3K

$694,067in research payments, 2019–2025

Across 35 payments — averaging $19,830 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Argenx US, Inc.$310K
Novartis$204K
HEMA Biologics, LLC$55K
Sanofi$42K
Sanofi US Services Inc.$33K
Incyte Corporation$25K
plus $26K from 2 others

What the payments were for

Consulting fees$10,00898%
Food & beverage$1812%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	2	$6,901
Sanofi	1	$3,288

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CABLIVI$3,288

How this compares

$10,189 in reported general payments places this provider in the 85th percentile of 193 hematology & oncology providers in Minnesota.

See all hematology & oncology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$13,852

Medicare patients

Services billed

147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EmpaveliPegcetacoplan	13	$689,882
SprycelDasatinib	12	$208,632
JakafiRuxolitinib Phosphate	13	$109,446
EliquisApixaban	131	$94,004
PromactaEltrombopag Olamine	11	$84,853
XareltoRivaroxaban	100	$65,034
Fondaparinux Sodium	11	$13,789
Tranexamic Acid	25	$8,082
Cyclosporine ModifiedCyclosporine, Modified	12	$1,407
Oxycodone Hcl	44	$1,085
Warfarin Sodium	21	$82
Methocarbamol	16	$66
Hydroxyzine Hcl	13	$34
Ibuprofen	11	$4
Tizanidine Hcl	12	$1

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
NovartisPromacta	$6,901	$84,85311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 193 hematology & oncology providers in Minnesota.

Other hematology & oncology in Minneapolis

Mark RedingMinneapolis$519K
Shilpa GuptaMinneapolis$421K
Vicki MorrisonMinneapolis$354K
Aimee MerinoMinneapolis$161K
Daniel WeisdorfMinneapolis$64K
Gautam JhaMinneapolis$55K
Arpit RaoMinneapolis$46K
Amit KulkarniMinneapolis$40K
Gregory VercellottiMinneapolis$34K
Veronika BachanovaMinneapolis$33K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →